Enasidenib (IDHIFA), targeting IDH2, and ivosidenib (TIBSOVO), IDH1, are administrated orally, blocking 2-HG in the blood of AML patients with IDH mutations. The gene discussed is IDH2; the disease is acute myeloid leukemia.